NeuroSigma is a life sciences company focused to developing bioelectronic technologies with the potential to transform medical practice and patients' lives. The firm engages TNS neuromodulation therapies based on intellectual property exclusively licensed from UCLA, including TNS therapies for ADHD, depression, PTSD and epilepsy. . The company's lead product includes external trigeminal nerve stimulation (TNS) system (eTNS system) --a novel neuromodulation therapy for a variety of neurological and neuropsychiatric disorders. Invented at the University of California, Los Angeles (UCLA), NeuroSigma is the exclusive worldwide licensee of UCLA's intellectual property portfolio related to this technology.a non-invasive system. The firm is also designing and developing subcutaneous TNS systems for patients who have responded to eTNS system and prefer an implantable system. With the firm's research efforts led by an experienced team of doctors, scientists, and engineers, use of TNS as a therapeutic platform is supported by over a decade of both basic science and clinical studies. To date, TNS has been investigated as a therapy for epilepsy, depression, attention deficity hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD), Lennox-Gastaut Syndrome (LGS) and traumatic brain injury (TBI).
